X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DISHMAN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DISHMAN PHARMA CADILA HEALTHCARE/
DISHMAN PHARMA
 
P/E (TTM) x 19.8 25.1 78.8% View Chart
P/BV x 4.7 3.3 140.1% View Chart
Dividend Yield % 0.9 0.7 131.5%  

Financials

 CADILA HEALTHCARE   DISHMAN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs558374 149.0%   
Low Rs362129 280.4%   
Sales per share (Unadj.) Rs116.3197.8 58.8%  
Earnings per share (Unadj.) Rs17.921.2 84.3%  
Cash flow per share (Unadj.) Rs23.134.7 66.6%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.80.8 95.8%  
Book value per share (Unadj.) Rs85.4179.9 47.5%  
Shares outstanding (eoy) m1,023.7480.69 1,268.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.3 310.8%   
Avg P/E ratio x25.711.9 216.8%  
P/CF ratio (eoy) x19.97.2 274.2%  
Price / Book Value ratio x5.41.4 384.8%  
Dividend payout %19.69.4 207.7%   
Avg Mkt Cap Rs m470,66420,306 2,317.9%   
No. of employees `00011.80.8 1,425.7%   
Total wages/salary Rs m18,5455,355 346.3%   
Avg. sales/employee Rs Th10,072.719,252.7 52.3%   
Avg. wages/employee Rs Th1,569.16,459.5 24.3%   
Avg. net profit/employee Rs Th1,547.72,064.1 75.0%   
INCOME DATA
Net Sales Rs m119,04915,961 745.9%  
Other income Rs m1,132265 426.5%   
Total revenues Rs m120,18116,226 740.7%   
Gross profit Rs m28,4754,103 694.0%  
Depreciation Rs m5,3881,091 494.0%   
Interest Rs m911944 96.5%   
Profit before tax Rs m23,3082,334 998.8%   
Minority Interest Rs m6280-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644624 905.1%   
Profit after tax Rs m18,2921,711 1,069.0%  
Gross profit margin %23.925.7 93.0%  
Effective tax rate %24.226.7 90.6%   
Net profit margin %15.410.7 143.3%  
BALANCE SHEET DATA
Current assets Rs m82,00511,018 744.3%   
Current liabilities Rs m60,7209,517 638.0%   
Net working cap to sales %17.99.4 190.1%  
Current ratio x1.41.2 116.7%  
Inventory Days Days73110 66.2%  
Debtors Days Days9835 282.2%  
Net fixed assets Rs m83,70316,304 513.4%   
Share capital Rs m1,024161 634.4%   
"Free" reserves Rs m86,42112,907 669.6%   
Net worth Rs m87,44514,516 602.4%   
Long term debt Rs m25,5514,189 609.9%   
Total assets Rs m180,65329,805 606.1%  
Interest coverage x26.63.5 765.9%   
Debt to equity ratio x0.30.3 101.2%  
Sales to assets ratio x0.70.5 123.1%   
Return on assets %10.68.9 119.3%  
Return on equity %20.911.8 177.5%  
Return on capital %22.017.5 125.4%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m42,6834,952 862.0%   
Fx outflow Rs m11,242697 1,613.4%   
Net fx Rs m31,4414,255 739.0%   
CASH FLOW
From Operations Rs m9,1932,786 329.9%  
From Investments Rs m-9,737-1,529 636.9%  
From Financial Activity Rs m515-941 -54.7%  
Net Cashflow Rs m-29316 -9.2%  

Share Holding

Indian Promoters % 74.8 61.4 121.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 3.7 224.3%  
FIIs % 5.9 12.7 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 22.1 49.8%  
Shareholders   44,069 46,261 95.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 26, 2018 03:37 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS